Tag: life sciences
-
Companies Recognized for Patient Safety Innovations
Three companies received awards for their products aimed at reducing the number of preventable deaths occurring in American hospitals.
-
Alliance to Study Brain Tumor Precision Diagnostics
A group of medical centers and companies, mainly in Philadelphia, is beginning a study of genomic profiling to diagnose brain tumors in adults and children.
-
Protein Drug Discovery Company Launches, Gains $50M
A biotechnology enterprise founded by faculty at Scripps Research Institute plans to discover new therapies based on complex interactions with human proteins.
-
Asthma Drug Tested as Alcoholism Treatment
Results from a small-scale clinical trial show an established drug to treat asthma and other inflammatory conditions has promise as a treatment for alcohol dependence.
-
EU Project to Develop More Versatile Heart Pacemakers
An initiative in Europe plans to design a new type of pacemaker device that adapts to a host of signals in the cardiovascular system and regulates multiple heart functions.
-
Grid Computing Harnessed for Childhood Cancer Research
An international consortium is seeking crowdsourced computing power to screen drug candidates for treating a number of cancers affecting children.
-
Low-Cost Skin Hydration Sensor and Systems Designed
Engineers at North Carolina State University in Raleigh developed a hydration sensor worn on the skin and built into two low-cost prototype wearable systems.
-
Smart Watch Software Designed to Verify Signatures
Engineering researchers in Israel created software that enables smart watches and fitness bands to capture wrist movements for verifying a person’s signature.
-
Novo Nordisk to Open Oxford Diabetes Research Center
The pharmaceutical company Novo Nordisk will build a research center to study type 2 diabetes on the campus of University of Oxford in the U.K.
-
Immunotherapy Biotech Raises $102 Million in IPO
A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering.